📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
232 analysed today
FollowTelegram
232
Today
149,633
All-time analysed
42,906
Positive
6,661
Negative
91,389
Neutral
8,609
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
37 announcements match the current filters (relevance ≥ 5).
Piramal Pharma Re-appoints Top Leadership and Approves FY26 Audited Financial Results
Piramal Pharma's Board has approved the audited financial results for the quarter and fiscal year ended March 31, 2026, with an unmodified audit opinion. The company ensured leadership stability by re-appointing Chairperson Nandini Piramal and CEO Peter DeYoung for three-year terms starting in 2027 and 2026, respectively. Additionally, Maneesh Sharma has been appointed as the new Company Secretary and Compliance Officer effective April 29, 2026. The board also extended the terms of two Independent Directors for five years each, starting in March 2027.
Key Highlights
Approved audited standalone and consolidated financial results for the full year ended March 31, 2026.
Re-appointed Ms. Nandini Piramal as Chairperson for a 3-year term effective April 1, 2027.
Re-appointed Mr. Peter DeYoung as Executive Director for a 3-year term effective October 6, 2026.
Appointed Mr. Maneesh Sharma as Company Secretary and KMP effective April 29, 2026, following the cessation of the interim officer.
Re-appointed Independent Directors Sridhar Gorthi and Peter Stevenson for second 5-year terms starting March 2027.
👀 What to Watch
Investors should take confidence in the leadership continuity and the clean audit report. Focus on the detailed financial performance metrics in the FY26 results to assess the company's growth trajectory.
Piramal Pharma Approves FY26 Results and Re-appoints Key Leadership for 3-5 Year Terms
Piramal Pharma's board has approved the audited financial results for the fiscal year ended March 31, 2026, with an unmodified audit opinion. The company ensured leadership stability by re-appointing Chairperson Nandini Piramal and Executive Director Peter DeYoung for three-year terms starting in 2027 and 2026, respectively. Furthermore, two independent directors were re-appointed for five-year terms, and a new Company Secretary was appointed. The board also authorized a change in the company's registered office address within Mumbai effective April 30, 2026.
Key Highlights
Approved audited standalone and consolidated financial results for FY26 with an unmodified auditor's opinion.
Re-appointed Ms. Nandini Piramal as Chairperson for a 3-year term effective April 1, 2027.
Re-appointed Mr. Peter DeYoung as Executive Director for a 3-year term effective October 6, 2026.
Extended terms for Independent Directors Sridhar Gorthi and Peter Stevenson for 5 years each starting March 2027.
Appointed Mr. Maneesh Sharma as Company Secretary and Compliance Officer effective April 29, 2026.
👀 What to Watch
Investors should review the detailed FY26 financial statements to assess the company's operational performance. The continuity in top management and the board is a positive sign for long-term strategic stability.
Piramal Pharma Approves FY26 Audited Results and Re-appoints Key Leadership
Piramal Pharma's board has approved the audited financial results for the fiscal year ended March 31, 2026, with auditors issuing an unmodified opinion. The company ensured leadership continuity by re-appointing Chairperson Nandini Piramal and CEO Peter DeYoung for additional 3-year terms. Additionally, two independent directors were re-appointed for 5-year terms, and Maneesh Sharma was named the new Company Secretary. The board also approved a change in the registered office address effective April 30, 2026.
Key Highlights
Approved audited standalone and consolidated financial results for the year ended March 31, 2026
Re-appointed Ms. Nandini Piramal as Chairperson for a 3-year term starting April 1, 2027
Re-appointed Mr. Peter DeYoung as Executive Director for a 3-year term starting October 6, 2026
Appointed Mr. Maneesh Sharma as Company Secretary and Compliance Officer effective April 29, 2026
Statutory auditors issued an unmodified opinion on the financial results for the period ended March 31, 2026
👀 What to Watch
Investors should review the detailed financial performance metrics for FY26 as leadership stability is now secured for the next three years. The unmodified audit opinion provides confidence in the reported financial integrity.
Piramal Pharma Receives US FDA EIR for Lexington Facility; Inspection Successfully Closed
Piramal Pharma Limited has received an Establishment Inspection Report (EIR) from the US FDA for its manufacturing facility located in Lexington, Kentucky, USA. The inspection, which was previously reported in December 2025, has been classified as Voluntary Action Indicated (VAI). This classification signifies the successful closure of the regulatory audit, ensuring the facility meets US compliance standards. The clearance is a positive development for the company's contract development and manufacturing operations in the US market.
Key Highlights
US FDA issued an Establishment Inspection Report (EIR) for the Lexington, USA manufacturing site.
The inspection status is classified as Voluntary Action Indicated (VAI), marking a successful closure.
The audit was originally initiated and disclosed on December 11, 2025.
Successful clearance ensures uninterrupted operations and compliance for products manufactured at this facility for the US market.
👀 What to Watch
This regulatory clearance removes a potential overhang on the stock and validates the company's quality systems. Investors should view this as a positive signal for the company's US-based manufacturing capabilities.
Piramal Pharma Completes Acquisition of Kenalog® Branded Injectable from Bristol-Myers Squibb
Piramal Pharma's subsidiary, Piramal Critical Care B.V., has successfully completed the acquisition of the Kenalog® brand and associated products from Bristol-Myers Squibb. This strategic move is aimed at strengthening the company's Complex Hospital Generics portfolio, which is a high-margin segment. The acquisition enhances Piramal's market presence across the United States, Europe, and the Asia Pacific region. This completion follows the initial agreement announced in January 2026, marking a significant milestone in the company's inorganic growth strategy.
Key Highlights
Successful completion of Kenalog® brand acquisition from Bristol-Myers Squibb (BMS).
Acquisition executed via Piramal Critical Care B.V., a step-down wholly owned subsidiary.
Strengthens the 'Complex Hospital Generics' portfolio across global markets.
Expands operational footprint in key geographies including the US, Europe, and Asia Pacific.
Follows through on the initial disclosure made on January 28, 2026.
👀 What to Watch
Investors should look for improved margins in the Critical Care segment as branded products typically offer better pricing power. Monitor upcoming quarterly earnings for the first full-quarter contribution of Kenalog® to the top line.
Piramal Pharma Resumes Operations at Dahej Site Following GPCB Revocation
Piramal Pharma Limited has received an interim revocation of the closure order for its Dahej manufacturing facility from the Gujarat Pollution Control Board (GPCB). The site, which was previously issued closure directions on February 4 and 12, 2026, under the Water Act, is now authorized to resume operations with immediate effect. This development follows a brief period of regulatory uncertainty regarding the plant's environmental compliance. The company is currently working with the GPCB to ensure the interim directions are made final in due course.
Key Highlights
GPCB granted interim revocation of closure directions for the Dahej site on February 13, 2026
Company authorized to resume operations at the facility with immediate effect
Closure was originally issued under Section 33A of the Water (Prevention and Control of Pollution) Act, 1974
Piramal Pharma is implementing measures to ensure the interim revocation is made final by the GPCB
👀 What to Watch
Investors should view this as a positive resolution to a potential production bottleneck; however, keep an eye on future compliance costs to ensure the revocation becomes permanent.
Piramal Pharma Digwal Facility Receives US FDA Form-483 with 4 Observations
Piramal Pharma Limited's manufacturing facility in Digwal, Telangana, underwent a US FDA inspection from February 9 to February 13, 2026. The inspection concluded with the issuance of a Form-483 containing 4 observations. These observations are procedural in nature and do not involve data integrity issues, which is a positive sign for the company's compliance culture. The US FDA has indicated a classification of Voluntary Action Indicated (VAI), suggesting that the findings are not critical to the facility's operational status.
Key Highlights
US FDA inspection conducted at Digwal, Telangana facility from Feb 9 to Feb 13, 2026
Issuance of Form-483 with 4 observations related to procedural enhancements
No data integrity issues were reported during the inspection
Preliminary classification indicated as Voluntary Action Indicated (VAI)
Company committed to submitting a detailed response within stipulated timelines
👀 What to Watch
Investors should view this as a routine regulatory event with manageable outcomes given the VAI classification and lack of data integrity issues. Monitor for the final Establishment Inspection Report (EIR) to confirm the closure of these observations.
Piramal Pharma Faces Rs 1 Crore Environmental Penalty for Dahej Plant
Piramal Pharma has been hit with an interim environmental damage compensation (EDC) of Rs. 1 crore by the Gujarat Pollution Control Board (GPCB). This penalty follows a previous closure direction issued on February 4, 2026, for the company's manufacturing facility located in Dahej, Gujarat. The company is currently engaging with regulatory authorities and the courts to seek an expedited resolution to the matter. Management states that beyond the EDC and a previously disclosed bank guarantee, there is no material impact on financial or operational activities at this time.
Key Highlights
GPCB imposed an interim environmental damage compensation of Rs. 1 crore on the Dahej site.
The penalty is linked to a closure direction issued under Section 33-A of the Water Act on February 4, 2026.
The affected facility is located at Plot No. D-2/11/A/1, GIDC Dahej, Bharuch, Gujarat.
Company is pursuing legal and regulatory channels to resolve the compliance issues and resume full operations.
👀 What to Watch
Investors should monitor the timeline for the lifting of the closure direction at the Dahej site, as prolonged downtime could affect production. While the Rs. 1 crore penalty is financially small, the regulatory oversight remains a point of concern for operational stability.
Piramal Pharma Partners with Blue-Zone to Recycle Waste Anesthetic Gases in Europe and Canada
Piramal Critical Care (PCC), a subsidiary of Piramal Pharma, has entered a strategic collaboration with Blue-Zone Technologies to capture and recycle waste anesthetic gases. The partnership will initially deploy Blue-Zone’s Phoenix Deltasorb technology in France and Germany, pending regulatory approval. PCC will process the captured gas to produce Sevoflurane USP in Canada, creating a sustainable full-lifecycle model for essential anesthetics. This initiative aligns with global ESG trends and leverages Piramal's existing distribution network across 100+ countries.
Key Highlights
Strategic collaboration to capture, collect, and recycle waste anesthetic gases using Blue-Zone technology.
Initial rollout targeted for France and Germany following European regulatory approval of the Phoenix Deltasorb system.
PCC will manufacture Sevoflurane USP from recycled gases at its Canadian facilities.
Leverages Piramal Pharma's global infrastructure of 17 facilities and distribution in over 100 countries.
👀 What to Watch
Investors should monitor the progress of regulatory approvals in Europe and the subsequent scaling of this technology. This move strengthens the company's ESG credentials and could provide a competitive edge in hospital procurement processes focused on sustainability.
Piramal Pharma Receives GPCB Closure Notice for Dahej Plant; Rs 15 Lakh Bank Guarantee Mandated
Piramal Pharma Limited has received a closure notice from the Gujarat Pollution Control Board (GPCB) for its manufacturing facility in Dahej, Gujarat. The notice, received on February 3, 2026, mandates the shutdown of industrial activities within 48 hours due to alleged violations of the Water Pollution Act. The company is also required to furnish a bank guarantee of Rs. 15,00,000. Piramal Pharma is contesting the order and is filing an urgent Writ Petition in the Gujarat High Court to seek an immediate stay on the closure.
Key Highlights
GPCB directed closure of the Dahej site within 48 hours of notice receipt on February 3, 2026
Alleged violations involve Section 33-A of the Water (Prevention and Control of Pollution) Act, 1974
Company must submit a bank guarantee of Rs. 15,00,000 with a one-year validity period
Piramal Pharma is seeking expedited intervention from the Gujarat High Court to reverse the order
Operational and financial impact of the potential shutdown is currently being evaluated
👀 What to Watch
Investors should monitor the Gujarat High Court's response to the Writ Petition as a prolonged shutdown could impact production schedules. The immediate focus should be on whether the company secures an interim stay to continue operations.
Piramal Pharma Q3 FY26: Revenue Down 3%, EBITDA Drops 32% Amid CDMO Headwinds
Piramal Pharma reported a weak Q3 FY26 with consolidated revenue declining 3% YoY to ₹2,140 crore and EBITDA falling 32% to ₹239 crore. The performance was primarily dragged down by the CDMO segment, which saw a 9% revenue dip due to inventory destocking and slow US biopharma funding. Despite these challenges, the Consumer Healthcare segment grew 20% YoY, and the company reported a recovery in order inflows starting October 2025. The company also announced the acquisition of the Kenalog brand for an upfront $35 million to bolster its Hospital Generics portfolio.
Key Highlights
Consolidated EBITDA margins contracted significantly to 11% in Q3FY26 from 16% in Q3FY25.
CDMO revenue fell 9% YoY to ₹1,166 crore, impacted by inventory destocking and regulatory delays at the Digwal facility.
Consumer Healthcare (PCH) segment grew 20% YoY, with power brands growing 30% and e-commerce sales up 50%.
Acquired Kenalog injectable from Bristol-Myers Squibb for $35M upfront plus up to $65M in contingent payments.
Reported a net loss of ₹136 crore for Q3FY26, compared to a profit of ₹4 crore in the previous year's quarter.
👀 What to Watch
Investors should exercise caution due to the sharp margin contraction and CDMO segment weakness, while monitoring if the 'early signs of recovery' in order inflows translate into a stronger Q4. The acquisition of Kenalog and the $90M US expansion are long-term positives, but short-term profitability remains under pressure.
Piramal Pharma Q3FY26: Revenue Down 3%, EBITDA Drops 32% Amid CDMO Headwinds
Piramal Pharma reported a weak Q3FY26 with consolidated revenue declining 3% YoY to ₹2,140 crore, primarily due to a 9% drop in the CDMO segment caused by inventory destocking and slower order inflows. EBITDA margins contracted significantly to 11% from 16% YoY, resulting in a net loss of ₹136 crore for the quarter. Despite the poor quarterly performance, the company noted a recovery in RFPs and order inflows since October 2025 and announced the acquisition of Kenalog for up to $100 million. Management expects the historically strong Q4 to drive a recovery in the final quarter of the fiscal year.
Key Highlights
Consolidated Revenue declined 3% YoY to ₹2,140 Cr, while EBITDA fell 32% to ₹239 Cr.
Reported a Net Loss of ₹136 Cr in Q3FY26 compared to a profit of ₹4 Cr in the previous year.
CDMO revenue dropped 9% YoY to ₹1,166 Cr, while Consumer Healthcare (PCH) grew 20% to ₹334 Cr.
Acquired Kenalog from Bristol-Myers Squibb for an upfront $35M and up to $65M in contingent payments.
E-commerce sales in the Consumer Healthcare segment grew 50% YoY, now contributing 26% of PCH sales.
👀 What to Watch
Investors should exercise caution due to the significant margin contraction and net loss, but monitor the promised recovery in Q4 and the impact of the Kenalog acquisition. The pick-up in CDMO order inflows since October 2025 is a key metric to watch for a potential turnaround in FY27.
Piramal Pharma Q3 Results: Consolidated Net Loss Widens to ₹136 Cr; Revenue Dips 3% YoY
Piramal Pharma reported a weak consolidated performance for Q3 FY26, with revenue from operations declining 2.9% YoY to ₹2,139.87 crore. The company swung to a consolidated net loss of ₹136.19 crore from a marginal profit of ₹3.68 crore in the previous year's corresponding quarter. Results were further weighed down by an exceptional charge of ₹41.11 crore on a consolidated basis due to the implementation of new Labour Codes. Despite the consolidated loss, standalone net profit showed a slight improvement, rising to ₹128.91 crore.
Key Highlights
Consolidated revenue from operations decreased by 2.9% YoY to ₹2,139.87 crore.
Reported a consolidated net loss of ₹136.19 crore compared to a profit of ₹3.68 crore in Q3 FY25.
Exceptional item of ₹41.11 crore recognized at the consolidated level for New Labour Code compliance.
Finance costs reduced to ₹89.24 crore from ₹103.31 crore in the year-ago period.
9-month consolidated net loss widened to ₹317.11 crore versus a loss of ₹62.37 crore in the previous year.
👀 What to Watch
The widening consolidated loss and stagnant revenue growth are concerning for short-term sentiment. Investors should exercise caution and wait for management commentary regarding the path to profitability and the impact of rising employee costs.
Piramal Pharma Announces Senior Management Changes and New Interim Company Secretary
Piramal Pharma has formally designated four senior officials as Senior Management Personnel (SMP) to lead critical functions including Quality, M&A, Legal, and HR. Ms. Tanya Sanish has resigned from her role as Company Secretary and Compliance Officer effective February 20, 2026, to pursue external opportunities. Ms. Pratibha Mishra, who has over 10 years of experience and has been with the firm since 2022, will take over as the Interim Company Secretary from February 21, 2026. The new SMPs bring significant expertise, with the heads of Quality and M&A each possessing over 25 years of industry experience.
Key Highlights
Four officials designated as Senior Management Personnel (SMP) including Chief Quality Officer and President-M&A
Ms. Rashida Najmi (CQO) and Mr. Jatin Lal (M&A) bring over 26 and 25 years of industry experience respectively
Company Secretary Tanya Sanish resigns effective February 20, 2026; Pratibha Mishra appointed as Interim CS
The new SMP team covers critical operational areas: Quality, M&A, Legal, and Human Resources
👀 What to Watch
These management changes represent a formalization of the leadership structure and a routine transition in the secretarial department. Investors should view this as neutral and continue to monitor the company's execution of its growth and M&A strategies.
Piramal Pharma to Acquire Kenalog Brand from BMS for Up to $100 Million
Piramal Pharma's subsidiary, Piramal Critical Care B.V., has signed a definitive agreement to acquire the Kenalog brand and associated trademarks from Bristol-Myers Squibb (BMS). The deal involves an upfront payment of $35 million and milestone-based contingent payments of up to $65 million. Kenalog is a branded injectable corticosteroid used for inflammatory conditions and is currently marketed across 15 countries. This acquisition is designed to strengthen Piramal's Complex Hospital Generics (CHG) portfolio and leverage its global distribution network.
Key Highlights
Total potential deal value of $100 million, including $35 million upfront and $65 million in milestones.
Acquisition includes multiple trademarks such as Kenalog, Kenacort, Trigon, and Adcortyl across 15 countries.
Target product is a synthetic corticosteroid indicated for rheumatoid arthritis and acute gouty arthritis.
Strategic fit to leverage Piramal's network of 6,000+ hospitals in over 100 countries.
Expansion focus specifically targets growth in the US, Europe, and Asia-Pacific markets.
👀 What to Watch
Investors should view this as a positive move to enhance the high-margin branded product portfolio. Monitor the impact on the Complex Hospital Generics segment's revenue growth and margin profile in the coming fiscal years.
Piramal Pharma's Lexington Facility Inspected by US FDA; Issues Form-483
The US FDA conducted a GMP inspection of Piramal Pharma's Lexington, USA facility from December 3rd to December 10th, 2025. Following the inspection, the US FDA issued a Form-483 with four observations. These observations are related to enhancements in procedures and are classified as VAI (voluntary action indicated). The company is preparing a detailed response to the observations for submission to the US FDA within the stipulated timelines.
Key Highlights
US FDA conducted GMP inspection from 3rd December, 2025 to 10th December, 2025
US FDA issued a Form-483 with four observations
Observations classified as VAI (voluntary action indicated)
👀 What to Watch
Investors should monitor the company's response to the FDA observations and any subsequent updates. While the observations are classified as VAI, any significant delays or negative findings could potentially impact future operations.
Piramal Pharma appoints Amit Soni as Non-Executive Independent Director
Piramal Pharma Limited has appointed Mr. Amit Soni as a Non-Executive Independent Director, effective February 9, 2026, for a term of five years, subject to shareholder approval. Mr. Soni is a Partner at CVC Capital and initiated its India business in 2017, deploying $980 million across 5 deals. He has over two decades of experience and has previously worked with General Atlantic, 3i, Bill & Melinda Gates Foundation, and McKinsey & Company. The company has confirmed that Mr. Soni is not debarred from holding the office of Director by any authority.
Key Highlights
Amit Soni appointed as Non-Executive Independent Director w.e.f. February 9, 2026
Mr. Soni to hold office for a term of five consecutive years
CVC Capital, led by Mr. Soni, has deployed $980 million across 5 deals in India
Mr. Soni has over two decades of experience
👀 What to Watch
Investors should monitor the performance and contributions of the new director. No immediate action is required.
